92806-98-9

Usage

Uses

Used in Pharmaceutical Industry:
5-HYDROXY-2-MERCAPTO-BENZIMIDAZOLE is used as a cytoprotective agent for the gastric mucosa. Its application is aimed at providing protection and healing to the stomach lining, which can be particularly beneficial for individuals suffering from gastric ulcers or other gastrointestinal disorders.
As a metabolite of leminoprazole, 5-HYDROXY-2-MERCAPTO-BENZIMIDAZOLE may also contribute to the overall effectiveness of the proton pump inhibitor in treating acid-related conditions, such as gastroesophageal reflux disease (GERD) or peptic ulcer disease. Its role in the pharmaceutical industry is crucial for developing new treatments and therapies for gastrointestinal health.

InChI:InChI=1/C7H6N2OS/c10-4-1-2-5-6(3-4)9-7(11)8-5/h1-3,10H,(H2,8,9,11)

Upstream product

• 610-81-1 4-hydroxy-2-nitroaniline 
• 75-15-0 carbon disulfide 
• 615-72-5 3,4-diaminophenol 
• 37052-78-1 5-methoxy-1,3-dihydro-2H-benzo[d]imidazole-2-thione 

Relevant academic research and scientific papers

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization

PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies. Besides, PRMT5 has been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments, with a Kd of 0.987 μM. Kinetic experiments indicated that 17 was a SAM competitive inhibitor other than the substrate. In addition, 17 showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to the inhibition of PRMT5 mediated SmD3 methylation. 17 may represent a promising lead compound to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.

COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a patient, including Pseudomonas aeruginosa infections, are also provided by the disclosure.